Relationship between the mechanisms of atherosclerosis and prostate cancer: literature review

Cover Page

Cite item

Full Text

Abstract

Cardiovascular disease and cancer remain the leading causes of hospitalization and death worldwide. Prostate cancer (PC) is one of the most common malignant diseases in men. Epidemiological studies have shown that the majority of patients with PC die not from cancer but from cardiovascular diseases, particularly coronary heart disease. In recent years, several studies have examined the relationship between atherosclerosis and PC, suggesting a stronger relationship than previously thought. Processing characteristics of the development and progression of both diseases include dysregulation of cell proliferation, oxidative stress, genetic changes, and inflammation. Despite conflicting data on the role of high cholesterol levels in the development of PC over the past decade, numerous studies have confirmed its importance in PC development and progression; meanwhile, statins have confirmed their value in reducing the risk of disease development and progression. The presented data confirm the need for a thorough assessment of cardiovascular risk factors, the presence of concomitant cardiovascular diseases in patients with PC, and the use of methods for the prevention and treatment of diseases associated with atherosclerosis to reduce cardiovascular risk and inhibit PC progression.

About the authors

Svetlana A. Pomeshkina

Research Institute for Complex Issues of Cardiovascular Diseases

Author for correspondence.
Email: swetlana.sap2@mail.ru
ORCID iD: 0000-0003-3333-216X
SPIN-code: 2018-0860

MD, Dr. Sci. (Med.)

Russian Federation, Kemerovo

Olga L. Barbarash

Research Institute for Complex Issues of Cardiovascular Diseases

Email: olb61@mail.ru
ORCID iD: 0000-0002-4642-3610
SPIN-code: 5373-7620

MD, Dr. Sci. (Med.), Professor, Academician of RAS

Russian Federation, Kemerovo

Evgeny V. Pomeshkin

Kemerovo State University

Email: pomeshkin@mail.ru
ORCID iD: 0000-0002-5612-1878
SPIN-code: 5661-1947

MD, Cand. Sci. (Med.), associate professor

Russian Federation, Kemerovo

Andrey I. Bragin-Maltsev

Kemerovo State Medical University

Email: bragin_maltsev@mail.ru
ORCID iD: 0000-0001-7102-2408
SPIN-code: 9130-7130

department assistant

Russian Federation, Kemerovo

References

  1. Writing Group Members; Mozaffarian D, Benjamin EJ, et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation. 2016; 133(4):e38–360. doi: 10.1161/CIR.0000000000000350
  2. Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25. doi: 10.1016/j.jacc.2017.04.052
  3. Khan MA, Hashim MJ, Mustafa H, et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020;12(7):e9349. doi: 10.7759/cureus.9349
  4. Yusuf S, Rangarajan S, Teo K, et al., Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371(9):818–827. doi: 10.1056/NEJMoa1311890
  5. Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and Cancer; A Resemblance with Far-reaching Implications. Arch Med Res. 2017;48(1):12–26. doi: 10.1016/j.arcmed.2017.03.005
  6. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
  7. Kaprin AD, Starinskii VV, Petrova GV, editors. Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii; 2018. (In Russ).
  8. Thomas JA 2nd, Gerber L, Bañez LL, et al. Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev. 2012;21(4):576–581. doi: 10.1158/1055-9965.EPI-11-1017
  9. Davis MK, Rajala JL, Tyldesley S, et al. The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada. J Oncol. 2015;2015:820403. doi: 10.1155/2015/820403
  10. Matthes KL, Pestoni G, Korol D, et al. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study. Urol Oncol. 2018;36(6):309.e15–309.e23. doi: 10.1016/j.urolonc.2018.02.016
  11. Zaorsky NG, Churilla TM, Egleston BL, et al. Causes of death among cancer patients. Ann Oncol. 2017;28(2):400–407. doi: 10.1093/annonc/mdw604
  12. Shin DW, Ahn E, Kim H, et al. Non-cancer mortality among long-term survivors of adult cancer in Korea: national cancer registry study. Cancer Causes Control. 2010;21(6):919–929. doi: 10.1007/s10552-010-9521-x
  13. Bhatia N, Santos M, Jones LW, et al. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Circulation. 2016;133(5):537–541. doi: 10.1161/CIRCULATIONAHA.115.012519
  14. Wallis CJ, Mahar AL, Satkunasivam R, et al. Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation. Urology. 2016;97:145–152. doi: 10.1016/j.urology.2016.08.002
  15. Abdollah F, Sammon JD, Reznor G, et al. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years. Eur J Surg Oncol. 2015;41(11):1529–1539. doi: 10.1016/j.ejso.2015.06.011
  16. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104–116. doi: 10.1038/nri3793
  17. Sarrazy V, Sore S, Viaud M, et al. Maintenance of macrophage redox status by ChREBP limits inflammation and apoptosis and protects against advanced atherosclerotic lesion formation. Cell Rep. 2015;13(1):132–144. doi: 10.1016/j.celrep.2015.08.068
  18. Ouimet M. Autophagy in obesity and atherosclerosis: Interrelationships between cholesterol homeostasis, lipoprotein metabolism and autophagy in macrophages and other systems. Biochim Biophys Acta. 2013;1831(6):1124–1133. doi: 10.1016/j.bbalip.2013.03.007
  19. Ross S, Stagliano NE, Donovan MJ, et al. Atherosclerosis and cancer: common molecular pathway of disease development and progression. Ann N Y Acad Sci. 2001;947:271–292;discussion 292–293.
  20. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368(21):2004–2013. doi: 10.1056/NEJMra1216063
  21. Yadav L, Puri N, Rastogi V, et al. Tumour angiogenesis and angiogenic inhibitors: a review. J Clin Diagn Res. 2015;9(6):XE01–XE05. doi: 10.7860/JCDR/2015/12016.6135
  22. Virmani R, Kolodgie FE, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25(10):2054–2061. doi: 10.1161/01.ATV.0000178991.71605.18
  23. Abi Khalil C. The emerging role of epigenetics in cardiovascular disease. Ther Adv Chronic Dis. 2014;5(4):178–187. doi: 10.1177/2040622314529325
  24. Sosa V, Moliné T, Somoza R, et al. Oxidative stress and cancer: An Overview. Ageing Res Rev. 2013;12(1):376–390. doi: 10.1016/j.arr.2012.10.004
  25. Dixon S, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10(1):9–17. doi: 10.1038/nchembio.1416
  26. de Nigris F, Sica V, Herrmann J, et al. c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in сancer and cardiovascular disease. Cell Cycle. 2003;2(4):325–328.
  27. Zhivotovsky B, Orrenius S. Cell cycle and cell death in disease: past, present and future. J Intern Med. 2010;268(5):395–409. doi: 10.1111/j.1365-2796.2010.02282.x
  28. Thompson MM, Garland C, Barrett-Connor E, et al. Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol. 1989;129(3):511–517. doi: 10.1093/oxfordjournals.aje.a115162
  29. Asia Pacific Cohort Studies Collaboration; Huxley R, Ansary-Mohaddam A, et al. The impact of modifiable risk factors on mortality from prostate cancer in populations of the Asia-Pacific region. Asian Pac J Cancer Prev. 2007;8(2):199–205.
  30. Kitahara CM, Berrington de Gonzalez A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29(12):1592–1598. doi: 10.1200/JCO.2010.31.5200
  31. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer. 2008;123(7):1693–1698. doi: 10.1002/ijc.23715
  32. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control. 2010;21(1):61–68. doi: 10.1007/s10552-009-9434-8
  33. Van Hemelrijck M, Garmo H, Holmberg L, et al. Prostate cancer risk in the Swedish AMORIS study. the interplay among triglycerides, total cholesterol, and glucose. Cancer. 2011;117(10):2086–2095. doi: 10.1002/cncr.25758
  34. Van Hemelrijck M, Walldius G, Jungner I, et al. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control. 2011;22(7):1011–1019. doi: 10.1007/s10552-011-9774-z
  35. Farwell WR, D’Avolio LW, Scranton RE, et al. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst. 2011;103(11):885–892. doi: 10.1093/jnci/djr108
  36. Shafique K, McLoone P, Qureshi K, et al. Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years’ follow up. BMC Cancer. 2012;12:25. doi: 10.1186/1471-2407-12-25
  37. Batty GD, Kivimaki M, Clarke R, et al. Modifiable risk factors for prostate cancer mortality in London. forty years of follow-up in the Whitehall study. Cancer Causes Control. 2011;22(2):311–318. doi: 10.1007/s10552-010-9691-6
  38. Simons K, Vaz WL. Model systems, lipid rafts, and cell membranes. Annu Rev Biophys Biomol Struct. 2004;33:269–295. doi: 10.1146/annurev.biophys.32.110601.141803
  39. Vidal-Vanaclocha F. Inflammation in the molecular pathogenesis of cancer and atherosclerosis. Reumatol Clin. 2009;5(Suppl 1):40–43. doi: 10.1016/j.reuma.2008.12.008
  40. Galbraith L, Leung HY, Ahmad I. Lipid pathway deregulation in advanced prostate cancer. Pharmacol Res. 2018;131:177–184. doi: 10.1016/j.phrs.2018.02.022
  41. Tosi MR, Bottura G, Lucchi P, et al. Cholesteryl esters in human malignant neoplasms. Int J Mol Med. 2003;11(1):95–98. doi: 10.3892/ijmm.11.1.95
  42. Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018;38(1):27. doi: 10.1186/s40880-018-0301-4
  43. Pelton K, Freeman MR, Solomon KR. Cholesterol and Prostate Cancer. Curr Opin Pharmacol. 2012;12(6):751–759. doi: 10.1016/j.coph.2012.07.006
  44. Aggarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605–1621. doi: 10.1016/j.bcp.2006.06.029
  45. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: Weighing the evidence. Eur Urol. 2013;63(5):800–809. doi: 10.1016/j.eururo.2012.11.013
  46. Hager M, Mikuz G, Bartsch G, et al. The association between local atherosclerosis and prostate cancer. BJU Int. 2007;99(1):46–48. doi: 10.1111/j.1464-410X.2006.06549.x
  47. Zhang X, Li G, Hu L, et al. Resistive index of prostatic capsular arteries as a predictor of prostate cancer in patients undergoing initial prostate biopsy. Med Oncol. 2014;31(12):297. doi: 10.1007/s12032-014-0297-9
  48. Di Francesco S, Robuffo I, Caruso M, et al. Metabolic Alterations, Aggressive Hormone-Naïve Prostate Cancer and Cardiovascular Disease: A Complex Relationship. Medicina (Kaunas). 2019;55(3):62. doi: 10.3390/medicina55030062
  49. Cuaron J, Pei X, Cohen GN, et al. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer. Brachytherapy. 2015;14(2):179–184. doi: 10.1016/j.brachy.2014.05.019
  50. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295(1):74–80. doi: 10.1001/jama.295.1.74
  51. Lustman A, Nakar S, Cohen AD, Vinker S. Statin use and incident prostate cancer risk: Does the statin brand matter? A population-based cohort study. Prostate Cancer Prostatic Dis. 2014;17(1):6–9. doi: 10.1038/pcan.2013.34
  52. Tan P, Wei S, Yang L, et al. The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis. Sci Rep. 2016;6:29106. doi: 10.1038/srep29106
  53. Van Rompay MI, Solomon KR, Nickel JC, et al. Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. Eur J Cancer. 2019;112:118–126. doi: 10.1016/j.ejca.2018.11.033
  54. Chen J, Zhang B, Chen D, Zhuang W. The association of statin use with risk of kidney, bladder and prostate cancer: a systematic review and meta-analysis of cohort studies. Int J Clin Exp Med. 2018;11(9):8873–8885.
  55. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California Men’s Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2218–2225. doi: 10.1158/1055-9965.EPI-07-0197

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies